$MD
Pediatrix Medical Group, Inc.

2018 Q2 Form 10-Q Financial Statement

#000119312518236651 Filed on August 02, 2018

View on sec.gov

Income Statement

Concept 2018 Q2
Revenue $915.9M
YoY Change 8.66%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $694.0M
YoY Change 4.46%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $26.52M
YoY Change 3.04%
% of Gross Profit
Operating Expenses $787.2M
YoY Change 9.18%
Operating Profit $128.7M
YoY Change 5.56%
Interest Expense $21.60M
YoY Change 16.56%
% of Operating Profit 16.79%
Other Income/Expense, Net -$19.15M
YoY Change 9.52%
Pretax Income $109.5M
YoY Change 4.89%
Income Tax $30.12M
% Of Pretax Income 27.5%
Net Earnings $79.41M
YoY Change 24.67%
Net Earnings / Revenue 8.67%
Basic Earnings Per Share $0.85
Diluted Earnings Per Share $0.85
COMMON SHARES
Basic Shares Outstanding 92.99M shares
Diluted Shares Outstanding 93.53M shares

Balance Sheet

Concept 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.00M
YoY Change -6.98%
Cash & Equivalents $38.06M
Short-Term Investments $9.900M
Other Short-Term Assets $14.22M
YoY Change 7.19%
Inventory
Prepaid Expenses $15.75M
Receivables $528.0M
Other Receivables $0.00
Total Short-Term Assets $624.9M
YoY Change 12.08%
LONG-TERM ASSETS
Property, Plant & Equipment $131.9M
YoY Change 19.41%
Goodwill $4.305B
YoY Change 9.03%
Intangibles
YoY Change
Long-Term Investments $90.20M
YoY Change 4.52%
Other Assets $92.63M
YoY Change 50.08%
Total Long-Term Assets $5.235B
YoY Change 7.94%
TOTAL ASSETS
Total Short-Term Assets $624.9M
Total Long-Term Assets $5.235B
Total Assets $5.860B
YoY Change 8.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $28.38M
YoY Change -6.55%
Accrued Expenses $329.9M
YoY Change 13.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $900.0K
YoY Change -96.67%
Total Short-Term Liabilities $411.2M
YoY Change 17.44%
LONG-TERM LIABILITIES
Long-Term Debt $1.891B
YoY Change 8.3%
Other Long-Term Liabilities $36.20M
YoY Change -20.86%
Total Long-Term Liabilities $36.20M
YoY Change -20.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $411.2M
Total Long-Term Liabilities $36.20M
Total Liabilities $2.673B
YoY Change 4.03%
SHAREHOLDERS EQUITY
Retained Earnings $2.153B
YoY Change 16.64%
Common Stock $1.034B
YoY Change 4.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.187B
YoY Change
Total Liabilities & Shareholders Equity $5.860B
YoY Change 8.36%

Cashflow Statement

Concept 2018 Q2
OPERATING ACTIVITIES
Net Income $79.41M
YoY Change 24.67%
Depreciation, Depletion And Amortization $26.52M
YoY Change 3.04%
Cash From Operating Activities $136.2M
YoY Change -1.02%
INVESTING ACTIVITIES
Capital Expenditures -$9.800M
YoY Change -3.92%
Acquisitions
YoY Change
Other Investing Activities -$7.000M
YoY Change 218.18%
Cash From Investing Activities -$16.80M
YoY Change 36.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -121.3M
YoY Change -4.26%
NET CHANGE
Cash From Operating Activities 136.2M
Cash From Investing Activities -16.80M
Cash From Financing Activities -121.3M
Net Change In Cash -1.900M
YoY Change 35.71%
FREE CASH FLOW
Cash From Operating Activities $136.2M
Capital Expenditures -$9.800M
Free Cash Flow $146.0M
YoY Change -1.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58056000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
93466848 shares
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40423000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
624930000
CY2018Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group
AssetsHeldForSaleNotPartOfDisposalGroup
46000000
CY2018Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
52098000
CY2018Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1390790000
CY2018Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
527997000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1032573000
CY2018Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
358255000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
28377000
CY2018Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1918787000
CY2018Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
144911000
CY2018Q2 us-gaap Assets
Assets
5859638000
CY2018Q2 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
30700000
CY2018Q2 us-gaap Cash Surrender Value Of Life Insurance
CashSurrenderValueOfLifeInsurance
15700000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38056000
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
93374000 shares
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93374000 shares
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
438017000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
34632000
CY2017Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1790034000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
225429000
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
934000
CY2018Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
126505000
CY2018Q2 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.490 pure
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
614226000
CY2018Q2 us-gaap Goodwill
Goodwill
4304740000
CY2018Q2 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
9902000
CY2018Q2 us-gaap Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
1000000
CY2018Q2 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
89186000
CY2018Q2 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
90186000
CY2018Q2 us-gaap Interest Payable Current
InterestPayableCurrent
5077000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
411213000
CY2018Q2 us-gaap Liabilities
Liabilities
2672716000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5859638000
CY2018Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
860000
CY2018Q2 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
35253000
CY2018Q2 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
1149500000
CY2018Q2 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
207687000
CY2018Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2400000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46475000
CY2018Q2 us-gaap Other Assets Current
OtherAssetsCurrent
14223000
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
92634000
CY2018Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15752000
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
36199000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
131922000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
19000000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2153415000
CY2018Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
3186922000
CY2018Q2 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
358255000
CY2018Q2 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
71379000
CY2018Q2 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
741612000
CY2018Q2 md Accrued Contingent Consideration Liability Current
AccruedContingentConsiderationLiabilityCurrent
26783000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55698000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
627235000
CY2017Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
92007000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1286035000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
503999000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1017328000
CY2017Q4 us-gaap Assets
Assets
5867278000
CY2017Q4 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
30500000
CY2017Q4 us-gaap Cash Surrender Value Of Life Insurance
CashSurrenderValueOfLifeInsurance
15600000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60200000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80200000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
93721000 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93721000 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
937000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
147797000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
639928000
CY2017Q4 us-gaap Goodwill
Goodwill
4283963000
CY2017Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
10292000
CY2017Q4 us-gaap Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
2121000
CY2017Q4 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
78561000
CY2017Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
80682000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4495000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
531425000
CY2017Q4 us-gaap Liabilities
Liabilities
2800824000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5867278000
CY2017Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1401000
CY2017Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
37912000
CY2017Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
1110500000
CY2017Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
212274000
CY2017Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
9200000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
53618000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
37160000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
91934000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15584000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
57905000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
123536000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2048189000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
20000000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
3066454000
CY2017Q4 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
438017000
CY2017Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
75672000
CY2017Q4 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
740923000
CY2017Q4 md Accrued Contingent Consideration Liability Current
AccruedContingentConsiderationLiabilityCurrent
6259000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14800000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5000 shares
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2740000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15275000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
18454000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51349000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.28
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
206780000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
194081000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1486000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
75692000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
1016000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
666000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-87862000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-15900000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3425000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-18361000
us-gaap Interest Expense
InterestExpense
36287000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2282000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
707000 shares
us-gaap Investment Income Net
InvestmentIncomeNet
941000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33860000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-139821000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8733000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
115813000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3407000
us-gaap Operating Expenses
OperatingExpenses
1450600000
us-gaap Operating Income Loss
OperatingIncomeLoss
227941000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
15324000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
21909000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
70192000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
113746000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1961000
us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
299000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3868000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13990000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
894000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
7290000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
821000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
754000000
us-gaap Profit Loss
ProfitLoss
118389000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
998000
us-gaap Share Based Compensation
ShareBasedCompensation
14781000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92977000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92270000 shares
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
58668000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1133803000
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1.00 pure
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20400000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
197000 shares
dei Amendment Flag
AmendmentFlag
false
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2212000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
24400000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22144000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-21211000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52681000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-100442000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-39909000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.53
dei Entity Central Index Key
EntityCentralIndexKey
0000893949
dei Entity Registrant Name
EntityRegistrantName
MEDNAX, INC.
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.54
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
216684000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
197021000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2782000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
54181000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
-5863000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1178000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
317000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
23998000
us-gaap Interest Expense
InterestExpense
41539000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1397000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
594000 shares
us-gaap Investment Income Net
InvestmentIncomeNet
2666000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-36091000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38974000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4774000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
21604000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2148000
us-gaap Operating Expenses
OperatingExpenses
1584663000
us-gaap Operating Income Loss
OperatingIncomeLoss
233112000
us-gaap Payments For Previous Acquisition
PaymentsForPreviousAcquisition
400000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
15884000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
26274000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
52160000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
25575000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
367000
us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
65000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9389000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
5995000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
821500000
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
22764000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
782500000
us-gaap Profit Loss
ProfitLoss
142840000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
636000
us-gaap Share Based Compensation
ShareBasedCompensation
20399000
dei Trading Symbol
TradingSymbol
MD
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
52200000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93516000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92922000 shares
md Payment For Purchase Consideration Related To Prior Period Acquisitions
PaymentForPurchaseConsiderationRelatedToPriorPeriodAcquisitions
1200000
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
62488000
md Increase Decrease In Accrued Payroll Taxes And Benefits
IncreaseDecreaseInAccruedPayrollTaxesAndBenefits
80500000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1252810000
md Number Of Physician Group Practices Acquired
NumberOfPhysicianGroupPracticesAcquired
5 Company
md Number Of Pediatric Subspecialty Practices Acquired
NumberOfPediatricSubspecialtyPracticesAcquired
2 Company
md Number Of Radiology Practices Acquired
NumberOfRadiologyPracticesAcquired
2 Company
md Number Of Neonatology Practices Acquired
NumberOfNeonatologyPracticesAcquired
1 Company
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1.00 pure
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7300000
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8000 shares
CY2017Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25735000
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.69
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.69
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
103015000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
104423000
CY2017Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
689000
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40725000
CY2017Q2 us-gaap Interest Expense
InterestExpense
18535000
CY2017Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
631000 shares
CY2017Q2 us-gaap Investment Income Net
InvestmentIncomeNet
365000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17481000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
721040000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
121904000
CY2017Q2 us-gaap Profit Loss
ProfitLoss
63698000
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92812000 shares
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92181000 shares
CY2017Q2 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
30872000
CY2017Q2 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
561418000
CY2017Q2 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1.00 pure
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10500000
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
392000 shares
CY2018Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26518000
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.85
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.85
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
107908000
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
109534000
CY2018Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1257000
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30122000
CY2018Q2 us-gaap Interest Expense
InterestExpense
21604000
CY2018Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
542000 shares
CY2018Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1202000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-19145000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
787239000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
128679000
CY2018Q2 us-gaap Profit Loss
ProfitLoss
79412000
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93529000 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92987000 shares
CY2018Q2 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
31833000
CY2018Q2 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
620980000
CY2018Q2 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1.00 pure

Files In Submission

Name View Source Status
0001193125-18-236651-index-headers.html Edgar Link pending
0001193125-18-236651-index.html Edgar Link pending
0001193125-18-236651.txt Edgar Link pending
0001193125-18-236651-xbrl.zip Edgar Link pending
d558671d10q.htm Edgar Link pending
d558671dex311.htm Edgar Link pending
d558671dex312.htm Edgar Link pending
d558671dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
md-20180630.xml Edgar Link completed
md-20180630.xsd Edgar Link pending
md-20180630_cal.xml Edgar Link unprocessable
md-20180630_def.xml Edgar Link unprocessable
md-20180630_lab.xml Edgar Link unprocessable
md-20180630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending